[johnnycakes78704]

ISIS Pharmaceuticals just signed a deal which is expected to skyrocket.

Genzyme and Isis inked a deal where Genzyme would buy $5M shares at $30 a share, and Genzyme will pay Isis $350M in licensing fees. Isis will also receive up to $750M in commercial milestone payments and $825M in development.

As per the deal, the profit will split 70/30 for Genzyme/Isis until the $2B mark is met and then each company will get 50% of the profits.

The drug is called Mipomersen and it is a cholesterol reduction drug.

This is expected to

[brownsfan019]

Originally Posted by johnnycakes78704 »

This is expected to

.... expected to....

oh, the suspense.

[johnnycakes78704]

Originally Posted by brownsfan019 »

.... expected to....

oh, the suspense.

sorry about that :p

The price is up to $19 this morning. Wachovia said this stock valuation will go to $30-$34 and another firm upped the target price from $20 to $26.